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Abstract
Background: The 6-month clinical outcome of patients
with multivessel disease enrolled in PURSUIT (Platelet
Glycoprotein IIb/IIIa in Unstable Angina: Receptor Sup-
pression Using Integrilin Therapy) is described. Patients
with complete angiography data were included; multi-
vessel disease was stratified according to the treatment
strategy applied early during hospitalization, i.e. medical
treatment, percutaneous coronary intervention (PCI)
(balloon), PCI (stent), or coronary artery bypass grafting
(CABG). Methods: Patients were divided into three
groups according to the treatment strategy applied dur-
ing the first 30 days of enrolment. Patients who did not
undergo a percutaneous or surgical coronary interven-
tion were classified as medically treated. Patients who
underwent a PCI (prior to a possible CABG) were sepa-
rated from those who underwent a CABG (prior to a pos-
sible PCI). The PCI group was further subdivided: pa-
tients receiving 61 coronary stents were separated from
those in whom no stents were used. Results: The mortal-
ity rate at 30 days was 6.7, 3.9, 2.4 and 4.8% for the medi-
cal treatment, PCI (balloon), PCI (stent) and CABG
groups, respectively (p value = 0.002). Differences as
observed at 30 days were still present at 6-month follow-
up with 11.1, 5.8, 5.5 and 6.5% mortality event rates for
the aforementioned groups (p value = 0.002). The 30-day
myocardial infarction (MI) rate according to the opinion
of the Clinical Events Committee was lower among med-
ically than non-medically treated patients, with the high-
est event rate observed in the CABG group (27.7%).
Approximately half of the MIs in the PCI and CABG sub-
groups occurred within 48 h after the procedure. Conclu-
sions: The observed differences in clinical outcomes are
explained by an imbalance in baseline characteristics
and comorbid conditions between the analyzed groups
of patients.
Copyright © 2002 S. Karger AG, Basel
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Introduction
Several clinical trials have been performed to evaluate
whether patients with coronary artery disease benefit
most from medical treatment only, percutaneous coro-
nary intervention (PCI), or coronary bypass surgery
(CABG) [1, 2]. Other studies have specifically compared
percutaneous transluminal coronary balloon angioplasty
(PTCA) against CABG [3–9] and finally contemporary
trials of coronary stenting and optimal adjunctive phar-
macological therapy versus CABG have recently been
reported [10–12]. However, most of these studies have
predominantly included patients with chronic stable angi-
na and few data are available on the characteristics and
clinical outcome of patients with multivessel disease pre-
senting with an acute coronary syndrome.
The Platelet Glycoprotein IIb/IIIa in Unstable Angina:
Receptor Suppression Using Integrilin Therapy (PUR-
SUIT) trial was a large-scale randomized clinical trial on
the effects of eptifibatide versus placebo in patients with
acute coronary syndromes without persistent ST eleva-
tion [13]. As the enrolment criteria were broad, PUR-
SUIT encompasses a wide variety of patients, hospital set-
tings and treatment policies, and therefore accurately
reflects standard clinical practice.
The aim of this study was to describe the characteris-
tics and short-term clinical outcome of patients with mul-
tivessel coronary artery disease in the PURSUIT popula-
tion according to the treatment strategy applied early dur-
ing hospitalization.
Materials and Methods
Patient Population
The design and methods of the PURSUIT trial have been pre-
viously published [13]. In summary, patients were eligible if they pre-
sented within 24 h of an episode of ischemic chest pain (110 min),
and had either transient ST elevation (10.5 mm), transient or persis-
tent ST depression (10.5 mm), T wave inversion (10.1 mm), or ele-
vation of the creatine kinase MB fraction (CK-MB) above the upper
limit of normal (ULN). Patients with persistent (130 min) ST eleva-
tion were excluded. Eligible patients were randomly assigned to treat-
ment with eptifibatide or placebo. All other treatment decisions,
including the use and timing of PCI or CABG were left at the discre-
tion of the treating physician.
Coronary angiography was performed within 30 days of enrol-
ment in 5,937 (63%) of the 9,461 patients who participated in PUR-
SUIT (fig. 1). Among patients with complete angiographic data,
3,067 (58%) had a significant stenosis (150% diameter stenosis by
visual inspection) in 62 major native coronary arteries or in the left
main stem. These patients were classified as having multivessel coro-
nary artery disease and are the subjects of interest for the current
analysis.
Classification According to Applied Treatment Strategy
Patients were divided into three groups according to the applied
treatment strategy during the first 30 days of enrolment. Patients
Fig. 1. PURSUIT patient population flow
chart stratified according to the number of
diseased vessels and treatment strategy ap-
plied to patients with multivessel coronary
disease. VD = vessel disease.
All patients
n = 9,461
Angiography
n = 5,937 (63%)
Complete data
n = 5,333 (90%)
0- or 1-VD
n = 2,266 (42%)
2- or 3-VD
n = 2,660 (50%)
Left main stem
n = 407 (8%)
Medical therapy
n = 901 (29%)
PCI-balloon
n = 533 (17%)
PCI-stent
n = 542 (18%)
CABG
n = 1,091 (36%)
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who did not undergo a percutaneous or surgical coronary interven-
tion were classified as medically treated. Patients who underwent a
PCI (prior to a possible CABG) were separated from those who
underwent a CABG (prior to a possible PCI). The PCI group was
further subdivided: patients receiving 61 coronary stents were sepa-
rated from those in whom no stents were used (fig. 1).
Definition of Myocardial Infarction
The primary endpoint of PURSUIT was a composite of death or
nonfatal myocardial infarction (MI) at 30 days. A computerized algo-
rithm was used to review the clinical events. If a possible event was
identified, further documentation was collected and the case re-
viewed in detail and adjudicated by a central Clinical Events Com-
mittee (CEC). MI was diagnosed on the basis of new ST segment
elevations, new Q waves, or new or repeated CK-MB elevations
above the ULN. Following percutaneous or surgical intervention, the
elevation of CK-MB level was required to be at least 3–5 times the
ULN.
Data Analysis
The statistical analysis was performed using the SAS 8.0 software
package (SAS Institute, Cary, N.C., USA). Continuous variables are
presented as mean values B standard deviation and dichotomous
variables as percentages. One-way analyses of variance (ANOVA)
and ¯2 tests were applied to evaluate differences in baseline charac-
teristics, death, MI rates and rates of repeated coronary interventions
(both at the 30-day and 6-month follow-up) between the different
subgroups classified according to the applied treatment strategy. In
case of a statistically significant difference in clinical events or
repeated coronary interventions, which was specified at the conven-
tional p ! 0.05 level, repeated tests were performed to further evalu-
ate the inter-subgroup differences. The Bonferroni method [14] was
used to avoid spurious significant results after multiple testing, and
the level of significance was lowered to p ! 0.0167 and p ! 0.0083 in
case of 3 (balloon – stent – surgery) and 6 possible comparisons (med-
ical treatment – balloon – stent – surgery), respectively.
Table 1. Clinical baseline characteristics
Medical
(n = 901)
PCI (n = 1,075)
balloon
(n = 533)
stent
(n = 542)
CABG
(n = 1,091)
Demographics
Mean age B SD, years 65B10 63B11 62B11 64B10***
Male gender, % 70 74 73 73
Caucasian, % 86 89 91 90*
Medical history and risk factors
Hypertension, % 62 60 61 57
Diabetes mellitus, % 30 26 23 27
Current smoker, % 28 29 29 26
Hypercholesterolemia, % 50 46 53 47
Prior PCI, % 17 23 23 14***
Prior CABG, % 36 24 29 9***
Prior MI, % 47 40 36 34***
Heart failure, % 14 8 10 6***
Prior CVA, % 7 4 5 3**
Peripheral vessel disease, % 13 8 9 9**
Cardiac medication prior to admission
Aspirin, % 73 74 76 74
Beta-blocker, % 48 50 49 49
Calcium antagonist, % 39 34 36 36
Nitrates, % 73 75 77 74
ACE inhibitors, % 30 23 24 21***
Clinical presentation
CK-MB 11 ULN, % 52 52 44 48*
ST depression 10.5 mm, % 52 47 52 58***
ST elevation 10.5 mm, % 12 17 15 13*
T wave inversion 10.5 mm, % 48 51 50 45
ACE = Angiotensin converting enzyme; CVA = cerebrovascular accident; other abbrevi-
ations, as defined in the text. Statistical tests (integral comparison of 4 groups): * p ! 0.05;
** p ! 0.01; *** p ! 0.001.
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Results
Patient Characteristics
During the first 30 days of randomization, a PCI was
performed in 1,075 of 3,067 (35%) patients, with stent
placement in 542 cases (50% of the PCI procedures),
whereas 1,091 of 3,067 (36%) patients underwent CABG.
The remaining 901 (29%) patients were medically treated
(fig. 1). A significant difference was evident between the
treatment subgroups with respect to age; medically
treated and CABG patients were older than those un-
dergoing PCI (table 1). There were also differences re-
garding history of prior cardiovascular events and inter-
ventions. Almost one quarter of the PCI patients had a
previous PCI versus 17 and 14% in the medical and surgi-
cal subgroups, respectively. A prior CABG was performed
in 36% of medically treated patients, and this figure was
only 9% in the CABG subgroup. A history of MI, heart
failure, cerebrovascular accident, as well as peripheral
vessel disease was more frequently observed in the medi-
cally versus non-medically treated patients. No important
differences were observed in the use of cardiac medica-
tions except for the use of ACE inhibitors, which was
more frequent in medically treated patients.
Angiographic Findings
Patients who underwent CABG had more severe coro-
nary artery disease (52% had 3-vessel and 21% left main
disease), immediately followed by medically treated pa-
tients with a similar percentage of 3-vessel disease (51%)
but less often, left main disease (11%) (table 2). A total
occlusion in any of the major native coronary arteries was
more often present in medically than in non-medically
treated patients. Medically and surgically treated patients
not only had more severe, but also more diffuse coronary
artery disease than PCI patients, as in 34% (CABG) to
40% (medically treated) of the patients, the culprit artery
could not be identified; this percentage was only 8–10% in
PCI patients. Left ventricular ejection fraction was lowest
among medically treated patients. There were no appar-
ent differences in coronary angiography results between
PCI patients receiving stents and those that did not
receive stents.
Clinical Outcome
The 30-day mortality rate was significantly higher
among medically treated patients (6.7%) than among
those undergoing PCI either with (2.4%) or without stent
placement (3.9%) (fig. 2). The observed difference in mor-
tality rate (p value = 0.067) between medically treated and
Table 2. Coronary angiography results
Medical PCI
balloon stent
CABG
Vessel disease, %
2 38** 62** 61** 28***
3 51 32 30 52
LM 11 6 9 21
Significant stenosis (DS 150%) in
RCA, % 84 79 81 85**
LAD, % 88 77 82 91***
LCX, % 84 77 72 79***
LM, % 12 6 10 22***
Total occlusion (DS = 100%) in
RCA, % 48 33 33 33***
LAD, % 35 24 26 20***
LCX, % 32 21 21 17***
Culprit artery, %
RCA 14 27 25 16***
LAD 21 25 29 29***
LCX 14 31 21 9
LM 2 1 1 9***
Graft 9 8 14 3***
None/unknown 40 8 10 34***
Mean LVEF B SD 50B16 55B14 54B14 53B14***
DS = Diameter of stenosis; LAD = left artery, descending; LCX =
left circumflex; LM = left main; LVEF = left ventricular ejection frac-
tion; RCA = right coronary artery; other abbreviations, as defined in
the text. Statistical tests (integral comparison of 4 groups): ** p !
0.01; *** p ! 0.001.
CABG patients (4.8% mortality) did not reach the re-
quired level of significance, which was prespecified as p !
0.0083.
The 30-day MI rate according to the opinion of the
CEC was lower among medically than non-medically
treated patients, with the highest event rate observed in
the CABG group (27.7%); approximately half of the MIs
in the PCI and CABG subgroups occurred within 48 h
after the procedure. Differences in event rates as observed
at 30 days were still present at the 6-month follow-up.
Mortality was highest in the medically treated subgroup
(11.1%). Mortality rates were similar in the non-medical
treatment subgroups (ranging from 5.5 to 6.5%). MI rates
as judged by the CEC were lowest in the medically treated
patients (20.8%) and highest in patients undergoing
CABG (29.6%).
Acute Coronary Syndromes and Multivessel
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Fig. 2. 30-day (a) and 6-month (b) clinical outcome according to the treatment strategy applied. Black bars indicate
mortality and white bars indicate MI adjudicated by the CEC. p Values for the overall comparison between any of the
treatment strategies applied (medical treatment, balloon, stent or surgery) and each clinical endpoint are as follows:
a death: p = 0.002, MI: p = 0.001 both at 30 days and 6 months.
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Fig. 3. 30-day (a) and 6-month (b) repeat revascularization procedures according to the treatment strategy applied.
Black bars indicate PCI and white bars indicate CABG. p Values for the overall comparison between any of the
re-interventions and each group based on the treatment strategy applied initially (medical treatment, balloon, stent or
surgery) are as follows: PCI, CABG: p ! 0.001 both at 30 days and 6 months.
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15.4
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11.1
6.3
0.7
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12
Repeat Revascularization Procedures
The rate of repeat revascularization at the 30-day and
6-month follow-up were significantly lower after CABG
than after PCI (fig. 3). Patients undergoing stent implan-
tation during the initial PCI had lower CABG rates at
each of these 2 points in time when compared to non-
stented patients. No apparent differences were observed
in the rates of repeat interventions between stented and
nonstented patients. A substantial number of medically
treated patients still underwent a PCI (4.6%) or CABG
(15.4%) procedure between 1 and 6 months after admis-
sion.
200 Cardiology 2002;98:195–201 Breeman/Mercado/Lenzen/van den Brand/
Harrington/Califf/Topol/Simoons/Boersma
Discussion
Patients who present with acute chest pain without
persistent ST segment elevation represent a heteroge-
neous population, which spans from noncardiac chest
pain (retrospectively diagnosed), to unstable angina and
acute MI. The uncertainty in early clinical diagnosis
forces clinicians to embark upon an empirical course of
treatment, and this is the main reason why the clinical
community still debates intensively regarding the optimal
treatment strategy for patients with non-ST elevation
acute coronary syndromes. Coronary angiography identi-
fies patients with nonsignificant coronary stenoses and
those with multivessel or left main disease. The former
group has an excellent prognosis with a low risk of pro-
gression to MI or death, whereas the latter group, which is
at an increased risk of progression to any of the aforemen-
tioned events, may derive a survival benefit from revascu-
larization (either PCI or CABG) [15, 16]. Patients who are
not suitable candidates for standard revascularization or
those who are at high risk of major perioperative compli-
cations due to comorbid conditions represent a distinct
category in which medical treatment is preferred.
A major goal in PURSUIT was to understand the het-
erogeneity of the patient population and treatment strate-
gies applied. The investigators therefore chose to embed
the study of the effects of epifibatide in a real-life clinical
setting including a broad spectrum of clinical practices,
from rural hospitals to major tertiary referral centers
around the world. To reflect actual clinical practice, no
recommendations were made regarding the use and tim-
ing of coronary angiography, percutaneous coronary in-
terventions or coronary bypass surgery, but all treatment
decisions were left at the discretion of the team of treating
physicians. Therefore, the results of the present descrip-
tive analysis should be interpreted with this background
in mind and viewed with the inherent limitations to sub-
group analysis of randomized clinical trials [17].
Although not prospectively randomized to each of the
treatment strategies compared, it is important to note that
the medical therapy, early PCI and CABG ratio in these
subgroups of 3,067 patients with an acute coronary syn-
drome and multivessel coronary artery disease was almost
1:1:1.
Indeed, important differences were observed in clini-
cal characteristics and coronary anatomy between the dis-
tinct subgroups. Patients who did not undergo a coronary
intervention within 30 days after enrolment, generally
were in a less favorable clinical condition than patients
undergoing early invasive treatment. The relatively high
30-day and 6-month mortality rate among medically
treated patients is therefore not surprising and argues for
the search of better treatment strategies in unstable pa-
tients with multivessel coronary artery disease that are
not good candidates for revascularization procedures. Im-
portant determinants in the decision to refrain from inva-
sive treatment in this patient population seem to be
comorbid conditions, left ventricular dysfunction (medi-
cally treated patients more often had a history of CABG,
heart failure, and a worse left ventricular function as com-
pared to CABG patients) and the extent of coronary
artery disease (medically treated patients more often had
3-vessel and left main disease as compared to PCI pa-
tients).
Limitations
This was a retrospective assessment of clinical, angio-
graphic characteristics and clinical events in patients
enrolled in a multicenter clinical trial and stratified ac-
cording to the treatment strategy applied with a follow-up
limited to 6 months, which can be considered as the main
caveat of this study. We lack data on anginal status at
baseline and 6 months; and on other predictors of adverse
outcome such as completeness of revascularization; in
both PCI and CABG patients. There were insufficient
data on postprocedural cardiac enzymes as well. How-
ever, the present analysis reflected standard practice in a
wide range of clinical settings, and contemporary treat-
ment strategies for the management of patients with acute
coronary syndromes and multivesel disease were used in
this trial.
Conclusions
The observed major differences in clinical outcome are
explained by an imbalance in baseline and angiographic
characteristics between the groups of patients analyzed
according to the treatment strategy applied.
Acute Coronary Syndromes and Multivessel
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